This is an archive article published on June 24, 2014
Premium

Clinical trials in India: Modi govt plans to clip wings of drug regulator

Clinical trial permissions have been stalled after SC rescinded regulator’s nod for 157 clinical trials.

Written by: Abantika Ghosh
2 min readNew DelhiJun 24, 2014 01:06 PM IST First published on: Jun 24, 2014 at 01:00 AM IST
Health Ministry is working on a proposal to provide accreditation to clinical trial centres, investigators and ethics committees. (Thinkstock) Health Ministry is working on a proposal to provide accreditation to clinical trial centres, investigators and ethics committees. (Thinkstock)

The Union Health Ministry is working on a proposal to provide accreditation to clinical trial centres, investigators and ethics committees — all of which will kept be out of the purview of Central Drugs and Standards Control Organisation, the country’s highest drug regulatory body. Thus, the role of CDSCO will be limited only to granting permission for testing new pharmaceutical products.

Clinical trial permissions have been stalled for months after the Supreme Court last year rescinded the regulator’s nod for 157 clinical trials. Based on the recommendations of the Professor Ranjit Roychowdhury Committee, the new regulatory model would take several aspects of clinical trials away from the CDSCO.

Latest Comment
Post Comment
Read Comments